# Therapy Toxicities

Rahul Shah

---

## Immune Checkpoint Inhibitor Toxicities

-	Immune checkpoint inhibitors augment the endogenous immune response against tumors, which may lead to autoimmune-like toxicities, known as immune-related adverse events (irAEs)
-	Treatment: low-dose glucocorticoids (prednisone, 0.5 mg/kg) for mild adverse events, high dose glucocorticoids (prednisone, 1-2 mg/kg) for severe adverse events

<table border="1">
  <tr>
    <th>Adverse Event Type</th>
    <th>Incidence with anti-CTLA-4<br>(e.g. ipilimumab)</th>
    <th>Incidence with anti-PD1/PD-L1<br>(e.g. nivolumab, pembrolizumab)</th>
  </tr>
  <tr>
    <td>Skin (rash, pruritus, TEN)</td>
    <td>30%</td>
    <td>30%</td>
  </tr>
  <tr>
    <td>Colitis</td>
    <td>25%</td>
    <td>5%</td>
  </tr>
  <tr>
    <td>Hypothyroidism</td>
    <td>20%</td>
    <td>20%</td>
  </tr>
  <tr>
    <td>Hepatitis</td>
    <td>10%</td>
    <td>1%</td>
  </tr>
  <tr>
    <td>Hypophysitis</td>
    <td>10%</td>
    <td>rare</td>
  </tr>
  <tr>
    <td>Pneumonitis</td>
    <td>2-5%</td>
    <td>2-5%</td>
  </tr>
  <tr>
    <td>Myocarditis</td>
    <td>&lt;1%</td>
    <td>&lt;1%</td>
  </tr>
  <tr>
    <td>Neurotoxicity (GBS, myasthenia gravis, encephalitis)</td>
    <td>&lt;1%</td>
    <td>&lt;1%</td>
  </tr>
</table>


## Cytotoxic Agent Toxicities

<table border="1">
  <tr>
    <th>Class</th>
    <th>Agent</th>
    <th>Side Effect</th>
  </tr>
  <tr>
    <td rowspan="3">Alkylating agents</td>
    <td>busulfan</td>
    <td>pulmonary fibrosis or diffuse alveolar hemorrhage</td>
  </tr>
  <tr>
    <td>cyclophosphamide</td>
    <td>myopericarditis, hemorrhagic cystitis (prevention: hydration; monitoring: daily UA, tx: mesna)</td>
  </tr>
  <tr>
    <td>ifosfamide</td>
    <td>encephalopathy (tx: methylene blue), nephrotoxicity, hemorrhagic cystitis</td>
  </tr>
  <tr>
    <td rowspan="5">Antimetabolites</td>
    <td>5-Fluorouracil (5-FU)/ Capecitabine (metabolized to FU)</td>
    <td>myelosuppression, coronary vasospasm, palmar-plantar erythrodysesthesia, mucositis</td>
  </tr>
  <tr>
    <td>cladribine, pentostatin</td>
    <td>dose reduced for CrCl</td>
  </tr>
  <tr>
    <td>cytarabine (Ara-C)</td>
    <td>irreversible cerebellar ataxia (if high dose, neuro checks required), conjunctivitis (prevent with prophylactic steroid eye drops)</td>
  </tr>
  <tr>
    <td>gemcitabine</td>
    <td>transient transaminitis, peripheral edema, rash, rarely: pulmonary toxicity, hemolytic uremic syndrome, capillary leak syndrome</td>
  </tr>
  <tr><td>methotrexate</td>
  <td>stomatitis, hepatotoxicity, renal failure, high dose requires leucovorin</td></tr>
  <tr>
    <td rowspan="2">Antitumor antibiotics</td>
    <td>anthracyclines (doxorubicin, daunorubicin, idarubicin)</td>
    <td>HFrEF (need TTE prior). Most notable with doxorubicin.</td>
  </tr>
  <tr>
    <td>bleomycin</td>
    <td>Pulmonary fibrosis. Potentiated with G-CSF</td>
  </tr>
  <tr>
    <td rowspan="3">Monoclonal antibodies</td>
    <td>alemtuzumab</td>
    <td>severe and prolonged cytopenias</td>
  </tr>
  <tr>
    <td>bevacizumab</td>
    <td>HFrEF, HTN, hyperglycemia, hypomag, DVT, pulm hemorrhage, GI bleeding/fistulas/perforation, wound healing complications</td>
  </tr>
  <tr>
    <td>rituximab</td>
    <td>hypophos, hepatotoxicity, HBV reactivation (screen all pts), peripheral neuropathy; transfusion reaction during 1st time infusion</td>
  </tr>
  <tr>
    <td>Platinum agents</td>
    <td>cisplatin, oxaliplatin, carboplatin</td>
    <td>Nephrotoxicity, worst with cisplatin. Rental tubular acidosis. Neurotoxicity (parasthesias, cold sensitivity, cramps, peripheral neuropathy), ototoxicity (high frequency hearing loss), constipation, hypomag</td>
  </tr>
  <tr>
    <td>Taxanes</td>
    <td>docetaxel, paclitaxel</td>
    <td>hypersensitivity reaction (often require premedication with steroids and H1/H2 blockers); peripheral neuropathy</td>
  </tr>
  <tr>
    <td>Topoisomerase inhibitors</td>
    <td>irinotecan, topotecan, etoposide</td>
    <td>irinotecan- acute diarrhea can be treated with atropine; delayed with atropine</td>
  </tr>
  <tr>
    <td>Tyrosine kinase inhibitors</td>
    <td>imatinib, dasatinib, nilotinib, bosutinib</td>
    <td>QTc prolongation, pulmonary effusion, hepatotoxicity</td>
  </tr>
  <tr>
    <td>Vinca alkaloid</td>
    <td>vincristine</td>
    <td>peripheral neuropathy and ototoxicity (vestibular system lost first)</td>
  </tr>
</table>
